Esperion Therapeutics, Inc. (ESPR)
Quantitative Summary
DeterministicFinancial health is average: Piotroski 4/9. Beneish M-Score of -1.97 exceeds the -2.22 academic threshold — earnings quality may warrant further review.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
ETF Contagion Visualizer
Simulate a price drop in Esperion Therapeutics, Inc. to visualize passive redemption contagion across ETFs and collateral stocks.
If Esperion Therapeutics, Inc. (ESPR) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Eli Lilly & Co. (LLY) as the most exposed collateral stock, sharing 2 ETFs with ESPR. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 3 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
ESPR Ownership Dynamics
ETFs with Highest ESPR Exposure
Float lock-up computed from 3 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-14 | 3,490 | $3.12 | $10,888.8 |
| 2026-05-13 | 180,408 | $3.13 | $564,677.04 |
| 2026-05-12 | 10,955 | $3.13 | $34,289.15 |
| 2026-05-11 | 7,500 | $3.14 | $23,550 |
| 2026-05-08 | 36,461 | $3.14 | $114,487.54 |
| 2026-05-07 | 244,391 | $3.15 | $769,831.65 |
| 2026-05-06 | 234,738 | $3.12 | $732,382.56 |
| 2026-05-05 | 351,980 | $3.12 | $1.1M |
| 2026-05-04 | 2,144,413 | $3.11 | $6.7M |
| 2026-05-01 | 563,578 | $2.00 | $1.1M |
| 2026-04-24 | 5,448 | $1.91 | $10,405.68 |
| 2026-04-23 | 3,879 | $1.97 | $7,641.63 |
| 2026-04-22 | 8,648 | $1.92 | $16,604.16 |
| 2026-04-15 | 4 | $2.05 | $8.2 |
| 2026-04-13 | 380 | $2.17 | $824.6 |
| 2026-04-09 | 11,296 | $2.33 | $26,319.68 |
| 2026-04-08 | 2,582 | $2.31 | $5,964.42 |
| 2026-04-01 | 150,000 | $2.74 | $411,000 |
| 2026-03-30 | 162 | $2.74 | $443.88 |
| 2026-03-27 | 9,054 | $2.85 | $25,803.9 |
| 2026-03-26 | 2,566 | $2.76 | $7,082.16 |
| 2026-03-25 | 12,697 | $2.62 | $33,266.14 |
| 2026-03-23 | 105,324 | $2.55 | $268,576.2 |
| 2026-03-19 | 17,179 | $2.51 | $43,119.29 |
| 2026-03-18 | 18,000 | $2.71 | $48,780 |
| 2026-03-13 | 81 | $2.47 | $200.07 |
| 2026-03-12 | 71,301 | $2.59 | $184,669.59 |
| 2026-03-06 | 36,312 | $2.77 | $100,584.24 |
| 2026-03-03 | 477 | $3.27 | $1,559.79 |
| 2026-02-13 | 3,265 | $3.40 | $11,101 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Compare ESPR to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.